Kyowa Kirin International plc.
Alina Tudor has over 15 years of work experience in the pharmaceutical industry. Currently, they are working at Kyowa Kirin International plc. in the role of Global Head, Medical Evaluation and ICSR Review as well as Deputy Head of Medical Safety since July 2023. Prior to this, they served as a Senior Director of Pharmacovigilance at the same company starting from April 2020. Before joining Kyowa Kirin International plc., Alina worked at Norgine as an Associate Director, Senior PV Physician/Deputy EU QPPV from April 2017 to April 2020. Alina also gained experience as an EU QPPV at Voisin Consulting Life Sciences from November 2014 to April 2017 and as an EUQPPV/Pharmacovigilance Manager at Alvogen from April 2010 to October 2014. Alina's earlier positions include Drug Safety Group Leader Safety Evaluation Team at Actavis from November 2006 to April 2010 and Medical Representative at Romastru Traiding in 2006.
Alina Tudor holds a Bachelor of Science (BSc) degree in Medicine from Carol Davila Medicine and Pharmacy University in Bucharest, which was obtained from 2000 to 2006. Prior to this, they attended CN IL Caragiale in Ploiesti from 1996 to 2000, although no degree or field of study is specified. Alina also attended Liceul Pedagogic Ploiesti, but no further information is given about their studies there. Additionally, they completed the EudraVigilance User Training Course offered by the European Medicines Agency sometime before 2010.
This person is not in any offices
Kyowa Kirin International plc.
At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas of oncology, nephrology and central nervous system (CNS) across Europe and the Middle East. KKI, headquartered in Marlow, England, and Galashiels, Scotland, is owned by Kyowa Kirin Co., Ltd (KKC), of Japan. Founded in 1949, KKC has a successful track record in Japan and has expanded globally. Our history of innovation is built on a strong legacy of scientific discovery and fostering collaborations that accelerate the delivery of innovative medicines to patients. Grounded in our expertise in antibody engineering, we continue to investigate new molecules with the potential to contribute to the future of healthcare and make a difference in the lives of patients. At KKI, it is our people who have helped make a real difference to our success. Working together, our employees excel in achieving results quickly and effectively, bringing diverse and unique viewpoints to the company to achieve our vision. Our passion and energy around our core values of commitment to life, innovation, integrity and teamwork help ensure that every day, each of us is focused on not just making medicines, but also making people smile. With our strong legacy and exciting future, KKI is looking for great people to join our team and support our commitment to life.